Sai Life Sciences Limited
₹1,559.70+₹64.75 (+4.3%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹19,113 Cr
- P/E
- 67.7x
- EV / EBITDA
- 62.4x
- Revenue
- ₹1,642 Cr
- Net margin
- 6.7%
- ROCE
- 15.3%
Price chart
Technical chartScreen technicals →+69.4% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- +2.2%
- 3M
- +18.7%
- 6M
- +45.7%
- 1Y
- +69.4%
- 5Y
- +122.1%
52-week range
Day change +₹64.75 (+4.3%) from ₹1,495 to ₹1,560 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in SAILIFE, bought on each weekday since 2024.
AI Summary
Indian StockStrengths1
- Revenue grew 15.7% YoY
Concerns1
- Low return on equity of 9.4%
Rule-based from financial data. Not advice.
About the company
Sai Life Sciences Limited operates as a contract research, development, and manufacturing organization (CRDMO) in India and internationally. It provides medicinal chemistry, pharmacokinetics, manufacturing, and contract development services. The company was formerly known as SAI Advantium Pharma Limited and changed its name to Sai Life Sciences Limited in July 2006. Sai Life Sciences Limited was incorporated in 1999 and is based in Hyderabad, India.
- Sector
- Healthcare
- Shares outstanding
- 21.1 Cr shares
- ISIN
- INE570L01029
- BSE code
- 544306
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹19,113 Cr
- P/E
- 67.7x
- P/B
- 8.2x
- EV / EBITDA
- 62.4x
- EV / Sales
- 13.9x
- P/S
- 13.5x
- Earnings yield
- 1.5%
- 52-week high
- ₹1,675.15
- 52-week low
- ₹796.40
Profitability
- Operating margin
- 20.3%
- Net margin
- 6.7%
- EBITDA margin
- 22.3%
- ROE
- 9.4%
- ROCE
- 15.3%
- ROA
- 4.2%
- Dividend payout
- 0.0%
- Tax rate
- 26.0%
- Other income, % of PBT
- 22.5%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹1,642 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 15.7%
- Revenue CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 14.4%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹317 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 63.4%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 82.1%
- Net profit CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 3.5%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹251 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 13.6%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹80.0 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 5.1%
Solvency and efficiency
- Current ratio
- 2.93
- Debt / Equity
- 0.86
- Debt / Assets
- 0.39
- Debt / EBITDA
- 2.74
- Interest coverage
- 3.56
- Financial leverage
- 2.22
- CFO / Net profit
- 2.64
- Cash / Market cap
- 5.1%
- Cash per share
- ₹46.36
- Asset turnover
- 0.63
- Fixed asset turnover
- 1.32
- Capital intensity
- 0.76
- Debtor days
- 67 days
- Inventory turnover
- 5.00
- Cash conversion cycle
- 25 days
Where the revenue went
Of every ₹100 of FY2025 revenue, ₹11 was left as net profit.
| From | To | Amount |
|---|---|---|
| Sales | Expenses | ₹1,248 Cr |
| Sales | Operating profit | ₹394 Cr |
| Operating profit | Interest | ₹72 Cr |
| Operating profit | Depreciation | ₹126 Cr |
| Operating profit | Profit before tax | ₹196 Cr |
| Other income | Profit before tax | ₹36 Cr |
| Profit before tax | Tax and other | ₹59 Cr |
| Profit before tax | Net profit | ₹173 Cr |
Revenue and net profit
Revenue grew 15.7% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹751 Cr | ₹65 Cr |
| FY2022 | ₹841 Cr | ₹16 Cr |
| FY2023 | ₹1,157 Cr | ₹24 Cr |
| FY2024 | ₹1,419 Cr | ₹95 Cr |
| FY2025 | ₹1,642 Cr | ₹173 Cr |
Cash flows
FY2025: ₹330 Cr from operations, -₹235 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | -₹26 Cr | -₹305 Cr |
| FY2022 | ₹88 Cr | -₹7 Cr |
| FY2023 | ₹221 Cr | ₹110 Cr |
| FY2024 | ₹251 Cr | ₹61 Cr |
| FY2025 | ₹330 Cr | -₹235 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹1,642 Cr+15.7%1Y
- Net profit
- ₹173 Cr+82.1%1Y
- Cash from operations
- ₹330 Cr
- Free cash flow
- -₹235 Cr-485.2%1Y
- Revenue CAGR, 5Y
- 14.4%
- EBITDA CAGR, 5Y
- 11.0%
- Net profit CAGR, 5Y
- 3.5%
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹1,642 Cr | ₹394 Cr | — | ₹173 Cr | ₹330 Cr | -₹235 Cr | 8.0% | +15.7% | +82.1% |
Monthly returns
Month-by-month returns of SAILIFE across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹3,137 Cr |
| Equity capital | ₹21 Cr |
| Reserves | ₹2,147 Cr |
| Borrowings | ₹287 Cr |
| Other liabilities | ₹682 Cr |
| Assets | ₹3,137 Cr |
| Fixed assets | ₹1,378 Cr |
| Capital work in progress | ₹124 Cr |
| Investments | ₹114 Cr |
| Other assets | ₹1,521 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
SAILIFE trades at 67.7x earnings against a peer median of 52.6x (a 29% premium).
Not shown (no positive earnings and no EV / Sales): JUBILANT PHARMOVA LIMITED.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Sai Life Sciences LimitedSAILIFEthis companyP/E ↑ premium | ₹19,113 Cr | 67.7x | 8.2x | 9.4% | 62.4x |
| AstraZeneca Pharma India Ltd.ASTRAZEN | ₹20,549 Cr | 88.9x | 25.7x | 22.8% | 86.6x |
| Onesource Specialty Pharma LimitedONESOURCE | ₹20,295 Cr | 76.8x | 3.4x | -98.0% | -92.4x |
| Eris Lifesciences LimitedERIS | ₹20,131 Cr | 71.4x | 7.3x | 11.9% | 45.5x |
| Neuland Laboratories Limited.NEULANDLAB | ₹18,376 Cr | 94.3x | 11.4x | 23.5% | 38.6x |
| Ventive Hospitality LimitedVENTIVE | ₹17,846 Cr | 91.9x | 3.9x | 49.7% | 60.7x |
| Poly Medicure LtdPOLYMED | ₹17,352 Cr | 49.8x | 6.0x | 17.3% | 42.5x |
| Cohance Lifesciences LimitedCOHANCE | ₹17,161 Cr | 46.3x | 3.9x | 14.6% | 37.0x |
| JUBILANT PHARMOVA LIMITEDJUBLPHARMA | ₹16,581 Cr | — | 7.4x | 1.3% | 140.4x |
| Peer median | — | 52.6x | 5.9x | 12.1% | 38.3x |
Year-to-date ROI
SAILIFE since 1 January, against earlier years.
Historical volatility
SAILIFE's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | 22.0% |
| FY2022 | 15.0% |
| FY2023 | 14.0% |
| FY2024 | 20.0% |
| FY2025 | 24.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹1,642 Cr |
| Costs | |
| Interest | ₹72 Cr |
| Expenses | ₹1,248 Cr |
| Operating profitOperating Profit | ₹394 Cr |
| Other income and charges | |
| Profit before tax | ₹232 Cr |
| Tax | |
| Net profitNet Profit | ₹173 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹3,137 Cr |
| Equity capitalEquity Capital | ₹21 Cr |
| Reserves | ₹2,147 Cr |
| Borrowings | ₹287 Cr |
| Other liabilitiesOther Liabilities | ₹682 Cr |
| AssetsTotal Assets | ₹3,137 Cr |
| Fixed assetsFixed Assets | ₹1,378 Cr |
| Capital work in progressCWIP | ₹124 Cr |
| Investments | ₹114 Cr |
| Other assetsOther Assets | ₹1,521 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹330 Cr |
| Investing cash flowCash from Investing Activity | -₹565 Cr |
| Financing cash flowCash from Financing Activity | ₹314 Cr |
| Change in cashNet Cash Flow | ₹80 Cr |
Learn while you research
Academy chapters picked for Sai Life Sciences Limited and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Valuation Multiples ExplainedThis stock trades at a P/E of 67.7, learn when high multiples are justified.6 min read
- 04 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 05 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read